Curettage-Electrodesiccation Treatment of Basal Cell Carcinomas

Kopf, Alfred W.; Bart, Robert S.; Schrager, David; Lazar, M. D.; Popkin, George L.

doi:10.1001/archderm.1977.01640040047006

Cited by 156 publications

(90 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All tumors with at least 5-year follow-up were included. The 5-year cure rate was compared with published cure rates for BCC treated with C&E. 1,2,[11][12][13][14][15][16][17][18] This study was approved by our institutional review board.…”

Section: Methodsmentioning

confidence: 99%

“…1,2 In addition, it has the potential to interact with implanted cardiac devices and delay healing. [3][4][5][6][7] Viral particles and potential carcinogens also have been identified in the smoke plumes of electrocautery devices.…”

mentioning

confidence: 99%

“…However, comparisons are difficult because many studies of C&E have lacked either the clinical or pathologic correlation that likely affects cure rates. 1,[12][13][14][15][16][17][18] The same is true of curettage alone. 2,11 We present a clinical and pathologic review of BCC treated with curettage alone and report on 5-year recurrence rates and the clinical and pathologic predictors of recurrence.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Treatment of basal cell carcinoma with curettage alone

Barlow

Zalla

Kyle

et al. 2006

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Treatment of basal cell carcinoma with curettage alone

Barlow

Zalla

Kyle

et al. 2006

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

“…Taut skin traction at the periphery is required for a firm plane. [14]. If during the curettage process, there is unexpected extensions or deeper involvement (reaches fat), the patient should be referred for margin control with excision or MMS.…”

Section: Electrodesiccation and Curettagementioning

confidence: 99%

Nonmelanoma skin cancer

Nguyen

2002

Curr. Treat. Options in Oncol.

111

View full text Add to dashboard Cite

Therapy for basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) does not end with treatment of the initial lesion because almost 50% of patients with one nonmelanoma skin cancer (NMSC) develop another NMSC in the next 5 years. An integrated program of skin cancer awareness, sun protection, and prophylactic approaches is critical. The risk profile of the tumor influences which therapies and specialties will be involved. Most NMSCs may be treated with outpatient methods. Primary care physicians may treat low-risk tumors, but dermatologists specially trained in cutaneous oncology and a multidisciplinary team should manage high-risk lesions. Superficial BCC and SCC may be treated adequately with superficial modalities such as electrodesiccation and curettage (EDC) and cryotherapy. Topical 5-fluorouracil is effective for small in situ lesions. Invasive but low-risk lesions may be treated with EDC and cryotherapy provided that the tumor is limited to the papillary dermis, is not recurrent, and does not have high-risk features. High-risk tumors are best treated with excision and histologic examination or Mohs micrographic surgery (MMS). MMS is the therapeutic gold standard for all NMSCs in terms of cure rates, margin control, and tissue conservation. Because of its higher cost and specialized process, MMS is best reserved for specific indications.

show abstract

“…They are associated with high cure rates for BCC (95%) and SCC (92%) [52,53]. Recurrence rates following this procedure are low at 3-6% for primary BCC <1 cm in size [54,55,56]. …”

Section: Classical Therapy Of Nmscsmentioning

confidence: 99%

Neoplastic Multifocal Skin Lesions: Biology, Etiology, and Targeted Therapies for Nonmelanoma Skin Cancers

Fernandes

Santos²,

Kovačević³

et al. 2017

Skin Pharmacol Physiol

View full text Add to dashboard Cite

Neoplastic skin lesions are multifocal, diffuse skin infiltrations of particular relevance in the differential diagnosis of ulcerative, nodular, or crusting skin lesions. Nonmelanoma skin cancers (NMSCs), namely, basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and also actinic keratosis (AK), are the most common malignant tumors in humans. BCCs do not proliferate rapidly and most of the times do not metastasize, while SCCs are more infiltrative, metastatic, and destructive. AKs are precursor lesions of cutaneous SCCs. The classical therapy of NMSCs makes use of photodynamic therapy associated with chemotherapeutics. With improved understanding of the pathological mechanisms of tumor initiation, progression, and differentiation, a case is made towards the use of targeted chemotherapy with the intent to reduce the cytotoxicity of classical treatments. The present review aims to describe the current state of the art on the knowledge of NMSC, including its risks factors, oncogenes, and skin carcinogenesis, discussing the classical therapy against new therapeutic options.

show abstract

Curettage-Electrodesiccation Treatment of Basal Cell Carcinomas

Cited by 156 publications

References 9 publications

Treatment of basal cell carcinoma with curettage alone

Treatment of basal cell carcinoma with curettage alone

Nonmelanoma skin cancer

Neoplastic Multifocal Skin Lesions: Biology, Etiology, and Targeted Therapies for Nonmelanoma Skin Cancers

Contact Info

Product

Resources

About